OptumRx is calling on pharmaceutical companies to deploy major changes toward rebates, according to a STAT report, but appears to be looking after its own bottom line.
The pharmacy benefit manager in December sent a letter to companies demanding seven-quarters notice before lowering drug prices, and wants rebates to remain proportional.
OptumRx’s letter applies only to drugs covered by Medicare Part D.
“Our goal in asking for advance notice of price changes in the lengthy Part D bid process is to achieve greater transparency and predictability in consumer premiums and out-of-pocket costs,” OptumRx said in a statement to Becker’s Hospital Review.
To read more on STAT, click here. (Paid subscription required)